Research funding and collaborations

Dr. Cem Meydan has contributed to competitively funded research programs across chromatin biology, blood cancers, cancer disparities, single-cell and spatial multi-omics, viral and microbial genomics, and spaceflight biology. His roles include co-investigator and key personnel, alongside computational research collaborations supported by the NIH, Blood Cancer United (formerly the Leukemia & Lymphoma Society), Cancer Grand Challenges, NASA, and other funders. Together, these programs demonstrate sustained experience in computational research across institutions, disciplines, and translational settings.

These are collaborative awards. Each entry identifies the program’s principal investigators and Dr. Meydan’s role separately. Historical participation predating the Meydan Lab is included for research context.

This is a selected list rather than a complete record of Dr. Meydan’s funded collaborations, and the outputs under each program are representative examples rather than full bibliographies. Further programs and publications may be added as records are reviewed.

Research areas and role attribution

Cancer epigenetics and gene regulation: BAF/SWI-SNF biology, chromatin looping, B-cell states, and lymphoma therapeutic vulnerabilities.
Computational and spatial multi-omics: integrative genomics, single-cell and spatial analysis, and molecular characterization across tissues and patient cohorts.
Infection, microbiome, and virome biology: computational profiling of microbial and viral communities, host responses, and diagnostic assays.
Spaceflight and systems biology: genomic and epigenomic analyses of molecular responses to spaceflight and environmental stress.

How grant roles and sources are documented

Grant roles follow Dr. Meydan’s professional funding records. Weill Cornell publicly lists his key-personnel role on SAMBAI. Many other public funder records name the award investigators but do not enumerate all co-investigators, key personnel, or scientific contributors.

A program principal investigator leads the named award. Participation in a project, subaward, or shared core does not imply responsibility for the full center budget or award administration.

Multiple cores within one center are grouped under their parent program. Award periods describe the funder’s project dates; individual participation periods are provided separately where they differ. Sources include official award records and publication acknowledgments, with archived copies (Internet Archive Wayback Machine or archive.today) when available.

Selected outputs include only publications coauthored by Dr. Meydan and research resources from the same studies. “Acknowledges” means the paper names that grant in its funding or acknowledgment statement; a paper may acknowledge several awards. Research tools and data portals are attributed to their development teams.

Additional formats: Markdown record · structured data.

Recent and multi-year funded programs

Programs with project periods extending into 2026 or later.

Cancer Grand Challenges · funded 2024

SAMBAI: cancer inequities in populations of African descent

Funder: Cancer Grand Challenges (Cancer Research UK and the U.S. National Cancer Institute)
Program: SAMBAI — Social, Ancestry, Molecular and Biological Analysis of Inequalities
Award period: Funded in 2024. Weill Cornell lists 2024–2029 (Cancer Research UK channel) and 2024–2026 (NCI channel).
Principal investigators: Melissa B. Davis (team lead, Morehouse School of Medicine)
Dr. Meydan’s role: Key personnel

SAMBAI combines large-scale genomic, molecular, environmental, and social data to investigate cancer inequities in populations of African descent. As key personnel, Dr. Meydan contributes computational expertise to molecular characterization and the development of analytical approaches for population-specific cancer research.

SAMBAI launched in 2024 and is in its data-generation phase; publications from the program are forthcoming.

The two Weill Cornell funding entries are channels within a single SAMBAI research initiative.

Sources

Source	What it documents	Archived copy
SAMBAI Cancer Grand Challenges	The team, its lead, year funded and research aims.	Wayback Machine
Cancer Grand Challenges funding awarded to study cancer inequity Weill Cornell Medicine Newsroom	Weill Cornell’s participation in the 2024 award.	Wayback Machine
Cem Meydan — faculty profile, Research section Weill Cornell VIVO	Dr. Meydan listed as key personnel on SAMBAI under Cancer Research UK (2024–2029) and the National Cancer Institute (2024–2026).	Wayback Machine

NIH / National Cancer Institute · 2025–2030

Lymphoma SPORE: addressing health disparities in lymphoma

Funder: NIH / National Cancer Institute
Program: Lymphoma Outcomes SPORE (Weill Cornell title: SPORE: Addressing Health Disparities in Lymphoma)
Award number: U54CA302435
Award period: August 2025 – July 2030 (NIH RePORTER; Weill Cornell record).
Principal investigators: Christopher R. Flowers (contact PI) and Jean L. Koff, MD Anderson Cancer Center. Weill Cornell subaward: Ari M. Melnick (co-principal investigator; leads Project 1) and Roberta Zappasodi (subaward principal investigator).
Dr. Meydan’s role: Computational research collaborator

The NCI Lymphoma Outcomes SPORE integrates tumor biology, clinical data, and population-level evidence to investigate disparities in lymphoma outcomes. Within the Weill Cornell research effort, Dr. Meydan contributes computational expertise to studies of B-cell states, immune signaling, and chromatin–microenvironment interactions, with an emphasis on biologically informed therapeutic vulnerabilities.

Selected outputs · 1 coauthored publication

The LMO2–LDB1–TAL1 complex regulates transcription networks in acute myeloid leukemia (2025) · Acknowledges U54CA302435
Coauthored study of the transcriptional networks of acute myeloid leukemia.

Components of this program

Project 1: Precision targeting of therapeutic vulnerabilities specific to African American lymphoma patients. Led by Ari M. Melnick (NIH RePORTER subproject listing).

Sources

Source	What it documents	Archived copy
Lymphoma Outcomes SPORE, U54CA302435 NIH RePORTER	Award number, principal investigators, project dates, projects and cores.	Wayback Machine
SPORE: Addressing Health Disparities in Lymphoma (Weill Cornell subaward) Weill Cornell VIVO	Weill Cornell subaward of U54CA302435, 2025–2030, and its Weill Cornell investigators.	Wayback Machine
Christopher Flowers, MD MD Anderson Cancer Center	The program’s contact principal investigator.	Wayback Machine

Blood Cancer United · October 2024 – September 2029

Epigenetic mechanisms and targeting in hematological malignancy

Funder: Blood Cancer United (formerly the Leukemia & Lymphoma Society)
Program: Epigenetic Mechanisms and Targeting in Hematological Malignancy — Specialized Center of Research (SCOR)
Award period: October 2024 – September 2029 (Blood Cancer United).
Principal investigators: Jonathan D. Licht (center principal investigator). Project 1, on chromatin looping in B-cell lymphoma, is led by Ari M. Melnick.
Dr. Meydan’s role: Computational genomics collaborator

This Blood Cancer United SCOR investigates epigenetic dysregulation and therapeutic vulnerabilities in hematologic malignancies. Dr. Meydan’s work within the lymphoma chromatin-looping effort applies computational approaches to CTCF, PDS5B, and loop extrusion, linking genome organization with B-cell gene regulation.

This center continues an earlier Leukemia & Lymphoma Society SCOR led by Dr. Licht (2019–2024, listed under Cancer research and translational programs). The two award cycles are separate entries.

Sources

Source	What it documents	Archived copy
Epigenetic Mechanisms and Targeting in Hematological Malignancy Blood Cancer United	Project term, center principal investigator and the five project descriptions, including Project 1 on DNA looping.	Wayback Machine
Jonathan Licht, MD Blood Cancer United	Dr. Licht as principal investigator of the SCOR program.	Not yet archived

NIH Common Fund · 2025–2030

VAST Center: Viromes Across Space(s) and Time

Funder: NIH Common Fund, Human Virome Program (administered by the National Institute on Aging)
Program: VAST Center: Viromes Across Space(s) and Time — Human Virome Characterization Center
Award number: U54AG089334
Award period: February 2025 – January 2030 (NIH RePORTER).
Principal investigators: Michael P. Snyder (contact PI), Ami S. Bhatt and Christopher E. Mason; led from Stanford University.
Dr. Meydan’s role: Computational and multi-omics collaborator

The NIH-funded VAST Center characterizes the human virome across people, body sites, environments, and time using longitudinal samples and molecular profiling. Dr. Meydan contributes computational and multi-omic research expertise to this multi-institutional effort, extending his work at the intersection of microbial genomics and human molecular biology.

The VAST Center launched in 2025 and is in its initial sample-collection and data-generation phase; center publications are forthcoming. An early coauthored study acknowledging the award is listed below.

Selected outputs · 1 coauthored publication

Systemic elevation of gut-derived p-cresol during one year in space (2026) · Acknowledges U54AG089334
Coauthored longitudinal metabolomic study from the NASA Twins Study.

Sources

Source	What it documents	Archived copy
Human Virome Program — Funded Research NIH Common Fund	The VAST Center among the funded Human Virome Characterization Centers, with its principal investigators.	Wayback Machine
VAST Center, U54AG089334 NIH RePORTER	Award number, principal investigators, institution and project dates.	Wayback Machine
Stanford Medicine awarded grant to study viral community in humans Stanford Medicine News Center	Center launch (May 2025), aims and principal investigators.	Wayback Machine

Blood Cancer United · October 2022 – September 2027

The immune niche in the development of hematological malignancies

Funder: Blood Cancer United (formerly the Leukemia & Lymphoma Society)
Program: The Immune Niche in the Development of Hematological Malignancies and Implications for Novel Therapy — Specialized Center of Research (SCOR)
Award number: LLS 7029-22 (Weill Cornell subaward for the single-cell core)
Award period: October 2022 – September 2027 (Blood Cancer United; Weill Cornell record).
Principal investigators: Tak W. Mak (center principal investigator, Princess Margaret Cancer Centre). At Weill Cornell: Christopher E. Mason (core lead and subaward principal investigator) and Ari M. Melnick (Project 2 lead).
Dr. Meydan’s role: Key personnel, in two components of the same program

This Blood Cancer United SCOR investigates how the immune and stromal environment shapes hematologic malignancies and creates treatment opportunities. As key personnel in its Weill Cornell components, Dr. Meydan contributes single-cell, spatial, and integrative computational analysis through the informatics core and the diffuse large B-cell lymphoma project.

The informatics core and the DLBCL project are components of the same SCOR award.

Selected outputs · 1 coauthored publication

The LMO2–LDB1–TAL1 complex regulates transcription networks in acute myeloid leukemia (2025) · Acknowledges LLS 7029-23/22
Coauthored acute myeloid leukemia study; the SCOR is acknowledged under the combined identifier.

Components of this program

Core B / Core 2: Spatial, Single-cell, and Integrative Informatics and Statistics Core. Led by Christopher E. Mason; Weill Cornell subaward LLS 7029-22. Weill Cornell record
Project 2: Genetically and epigenetically modified targets in the immune niche of diffuse large B-cell lymphoma. Led by Ari M. Melnick.

Sources

Source	What it documents	Archived copy
The Immune Niche in the Development of Hematological Malignancies and Implications for Novel Therapy Blood Cancer United	Project term, center principal investigator, and the projects and cores with their leads (Project 2: Ari Melnick; Core B: Christopher Mason).	Not yet archived
Immune Niche SCOR, Core 2 (LLS 7029-22) Weill Cornell VIVO	The Weill Cornell core subaward, its dates and investigators.	Wayback Machine

NIH / National Cancer Institute · 2022–2027

BAF complex deregulation in lymphoma

Funder: NIH / National Cancer Institute
Program: BAF complex deregulation in lymphoma
Award number: R01CA266279
Award period: August 2022 – July 2027 (NIH RePORTER).
Principal investigators: Michael R. Green (contact PI, MD Anderson Cancer Center) and Christopher E. Mason. Weill Cornell subaward: Christopher E. Mason (subaward principal investigator) and Ari M. Melnick (co-principal investigator).
Dr. Meydan’s role: Co-investigator

This NCI R01 investigates how BAF/SWI-SNF chromatin-remodeling defects contribute to lymphoma development and altered gene regulation. As a co-investigator, Dr. Meydan brings computational epigenomics and cell-state analysis expertise to the collaborative research. Related publications from the participating groups address ARID1A, SWI/SNF, and 3D genome organization.

Selected outputs · 4 coauthored publications · 2 resources

SWI/SNF complexes shape 3D chromatin architecture through CTCF and cohesin (2026) · Acknowledges R01 CA266279
Dr. Meydan is co-first and co-corresponding author and led the computational analyses.
ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors (2024) · Acknowledges R01 CA266279
Dr. Meydan is co-first author.
SMARCA4 is a haploinsufficient B-cell lymphoma tumor suppressor (2024) · Acknowledges R01CA266279
Coauthored study of SMARCA4 loss in B-cell lymphoma.
The LMO2–LDB1–TAL1 complex regulates transcription networks in acute myeloid leukemia (2025) · Acknowledges R01CA266279
Coauthored study of the transcriptional networks of acute myeloid leukemia.
Nature 2026 analysis code · Study resource · archived
Analysis code for the coauthored study.
ARID1A-related patent application · Study resource · archived
Related invention — named inventor.

Sources

Source	What it documents	Archived copy
BAF complex deregulation in lymphoma, R01CA266279 NIH RePORTER	Award number, principal investigators, institution and project dates.	Wayback Machine
BAF complex deregulation in lymphoma (Weill Cornell subaward) Weill Cornell VIVO	Weill Cornell subaward of R01CA266279, 2022–2027, and its Weill Cornell investigators.	Wayback Machine
Discovery suggests new strategy against follicular lymphoma Weill Cornell Medicine Newsroom	Related ARID1A research from the collaborating laboratories.	Wayback Machine

Cancer research and translational programs

Collaborations spanning lymphoma, leukemia, chromatin architecture, tumor immunity, and translational research.

NIH / National Cancer Institute · 2022–2027

Targeting the latency switch in EBV-associated lymphomas

Funder: NIH / National Cancer Institute
Program: Targeting Latency Switch in EBV+ Lymphomas
Award number: R37CA262517
Award period: July 2022 – June 2027 (NIH RePORTER). Held at Weill Cornell Medicine through February 2026, then transferred to NYU Grossman School of Medicine.
Principal investigators: Lisa Giulino Roth (principal investigator)
Dr. Meydan’s role: Key personnel

This NCI-funded research tests strategies to modify Epstein–Barr virus latency in lymphoma and improve the visibility of malignant cells to immune responses. Dr. Meydan contributed computational research expertise to the program’s investigation of viral gene regulation and epigenetic therapeutic strategies during his Weill Cornell participation.

Some public records end on February 28, 2026: that date closes the Weill Cornell period of the award. NIH RePORTER lists the continuation at NYU Grossman School of Medicine through June 30, 2027.

Sources

Source	What it documents	Archived copy
Targeting Latency Switch in EBV+ Lymphomas, R37CA262517 NIH RePORTER	Principal investigator, project dates and the 2026 change of institution.	Wayback Machine
R37CA262517 award detail HHS TAGGS	Award actions by fiscal year.	Wayback Machine
EBV-associated lymphomas Roth Lab, Weill Cornell Medicine	The research project and its aims.	Wayback Machine

NIH / National Cancer Institute · 2019–

Chromatin architecture and cancer progression

Funder: NIH / National Cancer Institute
Program: The Impact of Changes in Chromatin Architecture on Cancer Phenotypes and Tumor Progression
Award number: P01CA229086
Award period: Program project from June 2019; renewed, with current project dates through March 2030 (NIH RePORTER).
Principal investigators: Jane A. Skok (program principal investigator, NYU Grossman School of Medicine). Project leads in the first cycle included Ari M. Melnick (Project 2, the cohesin complex in myeloid leukemia) and Iannis Aifantis.
Dr. Meydan’s participation: 2019–2024 (Dr. Meydan’s records).
Dr. Meydan’s role: Key personnel

This NCI program examines how changes in 3D chromatin architecture alter gene regulation, cell identity, and cancer progression. Dr. Meydan contributed computational genomics expertise to the collaborative research during the 2019–2024 period of his involvement.

Selected outputs · 3 coauthored publications

SETD2 haploinsufficiency enhances AICDA mutagenesis in B-cell lymphoma (2022) · Acknowledges P01 CA229086
Coauthored study of SETD2 loss and AICDA mutagenesis in B-cell lymphoma.
Smc3 dosage regulates B-cell transit through germinal centers (2021) · Acknowledges P01 CA229086
Coauthored study of cohesin dosage in germinal-center B cells and lymphomagenesis.
Evolution of the epigenetic landscape in childhood B-ALL and drug resistance (2020) · Acknowledges P01 CA229086
Coauthored study of epigenetic evolution and drug resistance in childhood B-ALL.

Sources

Source	What it documents	Archived copy
The impact of changes in chromatin architecture on cancer phenotypes and tumor progression, P01CA229086 NIH RePORTER	Program principal investigator, project dates, and projects and cores with their leads.	Wayback Machine

NIH / National Cancer Institute · 2018–2025

Mechanism-based targeting of mantle cell lymphoma

Funder: NIH / National Cancer Institute
Program: Mechanism-Based Targeting of Mantle Cell Lymphoma
Award number: P01CA214274
Award period: September 2018 – August 2025 (NIH RePORTER).
Principal investigators: Selina Y. Chen-Kiang (program principal investigator, Weill Cornell Medicine)
Dr. Meydan’s participation: 2018–2024 (Dr. Meydan’s records).
Dr. Meydan’s role: Key personnel

This NCI program brought together molecular, functional-genomic, and statistical research to define dependencies and therapeutic opportunities in mantle cell lymphoma, including CDK4, FOXO and chromatin remodeling, and PRMT5. Dr. Meydan contributed computational biology expertise as key personnel in this multi-investigator translational research effort.

Selected outputs · 4 coauthored publications

PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma (2023) · Acknowledges P01 CA214274
Coauthored mantle cell lymphoma study.
The novel immunocompetent Eμ-SOX11CCND1 mouse model resembles human mantle cell lymphoma (2025) · Acknowledges P01CA214274
Coauthored study establishing an immunocompetent mantle cell lymphoma mouse model.
ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors (2024) · Acknowledges P01 CA214274
Coauthored B-cell lymphoma study; Dr. Meydan is co-first author.
Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis (2024) · Acknowledges P01CA214274
Coauthored lymphoma study.

Sources

Source	What it documents	Archived copy
Mechanism-Based Targeting of Mantle Cell Lymphoma, P01CA214274 NIH RePORTER	Program principal investigator, project dates, and projects and cores with their leads.	Wayback Machine

Leukemia & Lymphoma Society · 2019–2024

Targeting enhancer dysfunction in hematological malignancy

Funder: Leukemia & Lymphoma Society (now Blood Cancer United)
Program: Targeting Enhancer Dysfunction in Hematological Malignancy — Specialized Center of Research (SCOR)
Award number: LLS SCOR 7021-20
Award period: October 2019 – September 2024 (Dr. Meydan’s records).
Principal investigators: Jonathan D. Licht (center principal investigator); collaborators include Ari M. Melnick.
Dr. Meydan’s role: Key personnel (Core B)

This LLS Specialized Center of Research investigated enhancer dysfunction and epigenetic mechanisms in blood cancers. As key personnel in Core B, Dr. Meydan contributed computational research expertise to the center’s studies of dysregulated gene expression and therapeutic opportunities.

This is the award cycle before the 2024–2029 Blood Cancer United SCOR led by Dr. Licht (listed under Recent and multi-year funded programs). They are separate entries.

Selected outputs · 3 coauthored publications

SWI/SNF complexes shape 3D chromatin architecture through CTCF and cohesin (2026) · Acknowledges LLS SCOR 7021-20
Dr. Meydan is co-first and co-corresponding author.
ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors (2024) · Acknowledges LLS SCOR 7021-20
Dr. Meydan is co-first author.
Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis (2024) · Acknowledges LLS SCOR 7021-20
Coauthored lymphoma study.

Sources

Source	What it documents	Archived copy
Jonathan Licht, MD Blood Cancer United	Dr. Licht as principal investigator of a continuing LLS SCOR program.	Not yet archived
SWI/SNF complexes, CTCF and 3D genome organization (Nature, 2026) Nature	Funding statement: Ari Melnick supported by LLS SCOR 7021-20. Dr. Meydan is a co-first and co-corresponding author of the paper.	Wayback Machine

Leukemia & Lymphoma Society · 2016–2022

Epigenetics and DNA damage responses in hematologic disorders

Funder: Leukemia & Lymphoma Society (now Blood Cancer United)
Program: Therapeutic Implications of Altered Epigenetics and DNA Damage Responses in Hematologic Disorders — Specialized Center of Research (SCOR)
Award number: LLS 9238-16
Award period: 2016–2022 (program period stated by Blood Cancer United).
Principal investigators: Tak W. Mak (center principal investigator)
Dr. Meydan’s participation: 2016–2021 (Dr. Meydan’s records).
Dr. Meydan’s role: Key personnel (Core B)

This LLS SCOR examined the interaction of epigenetic abnormalities and DNA-damage responses in hematologic malignancies. Dr. Meydan contributed to its computational research core as key personnel, building experience across mechanistic cancer epigenomics and multi-investigator therapeutic research. The program preceded the 2022–2027 immune-niche SCOR led by Dr. Mak.

Selected outputs · 2 coauthored publications

ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors (2024) · Acknowledges LLS 9238-16
Dr. Meydan is co-first author.
The Space Omics and Medical Atlas (SOMA) and international astronaut biobank (2024) · Acknowledges LLS 9238-16
Dr. Meydan is co-corresponding author.

Sources

Source	What it documents	Archived copy
The Immune Niche in the Development of Hematological Malignancies (lay abstract) Blood Cancer United	States that Dr. Mak’s team held a previous LLS SCOR from 2016 to 2022.	Not yet archived
SOMA Browser — funding acknowledgments Weill Cornell Medicine	Lists LLS 9238-16 among the grants acknowledged by the SOMA Browser, whose code and visualizations are by Dr. Meydan.	Wayback Machine
Circulating miRNA spaceflight signature reveals targets for countermeasure development (Cell Reports, 2020) Cell Reports	A paper coauthored by Dr. Meydan whose funding statement lists “LLS 9238-16, Mak”.	Not yet archived

Leukemia & Lymphoma Society · 2012 award cycle

Chromatin mechanisms and epigenetic targeting in hematological malignancies

Funder: Leukemia & Lymphoma Society (now Blood Cancer United)
Program: Marshall A. Lichtman Specialized Center of Research (SCOR) led by Jonathan Licht, 2012 award cycle (project title in Dr. Meydan’s records: Chromatin Mechanisms and Epigenetic Targeting in Hematological Malignancies)
Award period: Five-year award announced by LLS in September 2012.
Principal investigators: Jonathan D. Licht (center principal investigator, then at Northwestern University), with co-investigators at Rockefeller University, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center and the University of Michigan.
Dr. Meydan’s participation: 2015–2017 (Dr. Meydan’s records).
Dr. Meydan’s role: Key personnel

This earlier LLS SCOR brought together investigators studying chromatin regulation and epigenetic targets in leukemia, lymphoma, and myeloma. Dr. Meydan served as key personnel within the Weill Cornell collaboration during the later years of this award cycle.

Dr. Licht’s SCOR program has been funded in successive award cycles. The 2019–2024 and 2024–2029 cycles are separate entries.

Sources

Source	What it documents	Archived copy
Licht receives grant for blood cancer research Northwestern University Feinberg School of Medicine	The 2012 SCOR award to Dr. Licht, its five-year term and its co-investigator institutions, including Weill Cornell.	Wayback Machine
Licht Lab news (reproduces the LLS press release of September 5, 2012) Licht Lab, OpenWetWare	LLS’s announcement of the four 2012 SCOR awards and the scientific aims of Dr. Licht’s center.	Wayback Machine

Starr Cancer Consortium · thirteenth grant competition

Dietary regulation of cancer immunity

Funder: Starr Cancer Consortium (The Starr Foundation)
Program: Dietary regulation of cancer immunity — Thirteenth Starr Cancer Consortium Grant Competition
Award number: I13-0052
Award period: Awarded in the consortium’s thirteenth grant competition, listed on the consortium’s site by December 2019.
Principal investigators: Semir Beyaz (principal investigator, Cold Spring Harbor Laboratory); co-principal investigators Christopher E. Mason (Weill Cornell Medicine) and Kıvanç Birsoy (The Rockefeller University).
Dr. Meydan’s participation: 2020–2021 (Dr. Meydan’s records).
Dr. Meydan’s role: Co-investigator

This Starr Cancer Consortium project linked nutrition, immune responses, and cancer biology across Cold Spring Harbor Laboratory, Weill Cornell Medicine, and The Rockefeller University. As a co-investigator, Dr. Meydan contributed computational and multi-omic research expertise. Published studies he coauthored acknowledge support from this award.

Selected outputs · 4 coauthored publications · 3 resources

Diverse high-fat diets drive multi-omic reprogramming that persists after dietary reversal (preprint) (2026) · Acknowledges I13-0052
bioRxiv preprint; Dr. Meydan is co-corresponding author, credited with data curation, formal analysis, software, visualization, supervision, and writing.
SETD2 haploinsufficiency enhances AICDA mutagenesis in B-cell lymphoma (2022) · Acknowledges I13-0052
Coauthored B-cell lymphoma study.
Smc3 dosage regulates B-cell transit through germinal centers (2021) · Acknowledges I13-0052
Coauthored study of cohesin dosage in germinal-center B cells.
Haplotype diversity and sequence heterogeneity of human telomeres (2021) · Acknowledges I13-0052
Coauthored genome-assembly study of human telomeres.
Diet–microbiome multi-omics explorer · Study resource · archived
Interactive explorer for the diet multi-omics data, hosted by the study team.
Diet study analysis code and metadata · Study resource · archived
Analysis scripts and data manifests for the diet study, from the study team.
Diet study multi-omics dataset · Study resource · archived
Multi-omics dataset listed in the preprint’s data-availability statement.

Sources

Source	What it documents	Archived copy
Thirteenth Starr Cancer Consortium Grant Competition Starr Cancer Consortium	The project, its principal investigator and co-principal investigators.	Wayback Machine
Dietary suppression of MHC class II expression in intestinal epithelial cells enhances intestinal tumorigenesis (Cell Stem Cell, 2021) Cell Stem Cell	Research from the Beyaz laboratory supported by I13-0052.	Not yet archived
Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation (Nature Immunology, 2021) Nature Immunology	A paper coauthored by Dr. Meydan that acknowledges Starr Cancer Consortium I13-0052.	Not yet archived
Haplotype diversity and sequence heterogeneity of human telomeres (Genome Research, 2021) Genome Research	A paper coauthored by Dr. Meydan that acknowledges STARR I13-0052.	Not yet archived

NIH / National Cancer Institute · 2019–2026

ECOG-ACRIN Integrated Leukemia Translational Science Center

Funder: NIH / National Cancer Institute
Program: ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)
Award number: UG1CA233332
Award period: March 2019 – February 2026 (NIH RePORTER). The center was established in 2019.
Principal investigators: Ross L. Levine and Omar Abdel-Wahab (contact PIs, Memorial Sloan Kettering Cancer Center), with Ari M. Melnick, Adolfo A. Ferrando and Sheng Cai.
Dr. Meydan’s role: Key personnel

The NCI-supported ECOG-ACRIN Leukemia Integrated Translational Science Center connects clinical leukemia studies with molecular profiling, biomarker research, and analytical resources. Dr. Meydan contributed computational expertise as key personnel in the associated collaborative translational research.

Sources

Source	What it documents	Archived copy
ECOG-ACRIN Integrated Leukemia Translational Science Center, UG1CA233332 NIH RePORTER	Award number, principal investigators, institution and project dates.	Wayback Machine
Leukemia Integrated Translational Science Center ECOG-ACRIN Cancer Research Group	The center’s purpose and establishment in 2019.	Wayback Machine
UG1CA233332 award detail HHS TAGGS	Award actions by fiscal year.	Wayback Machine

Microbiome, infection, and spatial profiling

Research connecting computational analysis to microbial diagnostics and tissue-resolved cancer biology.

NIH / NIAID · 2020–2026

Urinary cell-free DNA to monitor infection after kidney transplantation

Funder: NIH / National Institute of Allergy and Infectious Diseases
Program: Metagenomic profiling of urinary cell-free DNA to monitor urinary tract infection after kidney transplantation
Award number: R01AI151059
Award period: March 2020 – February 2026, including a no-cost extension (NIH RePORTER).
Principal investigators: Iwijn De Vlaminck (contact PI, Cornell University), Christopher E. Mason and Darshana Dadhania (Weill Cornell Medicine)
Dr. Meydan’s participation: 2020–2025 (Dr. Meydan’s records).
Dr. Meydan’s role: Key personnel

This NIH-supported Cornell–Weill Cornell collaboration investigated metagenomic profiling of urinary cell-free DNA for infection monitoring after kidney transplantation. As key personnel, Dr. Meydan contributed computational and molecular-data expertise to research on noninvasive microbial diagnostics.

Selected outputs · 2 coauthored publications

Improved gastrointestinal health for irritable bowel syndrome with metagenome-guided interventions (2020) · Acknowledges R01AI151059
Co-first-authored study of metagenome-guided interventions in irritable bowel syndrome.
Transcriptional response modules characterize IL-1β and IL-6 activity in COVID-19 (2021) · Acknowledges R01AI151059
Coauthored study of IL-1β and IL-6 transcriptional response modules in COVID-19.

Sources

Source	What it documents	Archived copy
Metagenomic profiling of urinary cell-free DNA…, R01AI151059 NIH RePORTER	Award number, principal investigators, institution and project dates.	Wayback Machine
Intercampus team to develop post-transplant UTI diagnosis Cornell Chronicle	The 2020 award announcement and its investigators.	Wayback Machine
Intercampus collaboration awarded grant to develop method for diagnosing urinary tract infections Weill Cornell Medicine Research	Weill Cornell announcement of the award.	Wayback Machine

Gastro-Intestinal Research Foundation · 2022–2024

A spatially resolved molecular atlas of colorectal cancer

Funder: Gastro-Intestinal Research Foundation (CA CURE)
Program: Colorectal Cancer (CRC) Cellular Heterogeneity, Metastasis, and a Spatially-resolved Molecular Atlas for the Colon
Award period: 2022–2024 (Dr. Meydan’s participation period).
Principal investigators: Christopher E. Mason (principal investigator)
Dr. Meydan’s role: Key personnel

This Gastro-Intestinal Research Foundation project applied spatially resolved RNA and protein profiling to colorectal cancer heterogeneity, tissue organization, and metastasis. Dr. Meydan contributed computational expertise as key personnel, extending his spatial-omics research into solid-tumor biology.

Sources

Source	What it documents	Archived copy
CA CURE research grants Gastro-Intestinal Research Foundation	The funded project and its lead investigator.	Wayback Machine

Spaceflight and interdisciplinary genomics

NASA-supported molecular spaceflight research and earlier integrative genomics programs.

NASA · December 2021 – November 2024

Spatiotemporal mapping of spaceflight effects on heart and brain

Funder: NASA Space Biology
Program: Spatiotemporal Mapping of the Impact of Spaceflight on the Heart and Brain
Award number: 80NSSC22K0254
Award period: December 2021 – November 2024 (NASA Task Book).
Principal investigators: Christopher E. Mason (principal investigator); co-investigators Sylvain Costes and Jonathan Galazka (NASA Ames) and Stefania Giacomello (KTH)
Dr. Meydan’s role: Key personnel

This NASA program investigated the molecular effects of spaceflight in heart and brain using spatial transcriptomics, single-cell profiling, and integrative analysis. As key personnel, Dr. Meydan contributed computational research expertise to the study of tissue- and cell-specific responses.

Selected outputs · 3 coauthored publications · 1 resource

Spatial multi-omics of human skin reveals KRAS and inflammatory responses to spaceflight (2024) · Acknowledges 80NSSC22K0254
Coauthored spatial multi-omics study of skin samples from spaceflight.
Single-cell multi-ome and immune profiles of the Inspiration4 crew (2024) · Acknowledges 80NSSC22K0254
Coauthored single-cell multi-ome study of the Inspiration4 crew.
The Space Omics and Medical Atlas (SOMA) and international astronaut biobank (2024) · Acknowledges 80NSSC22K0254
Dr. Meydan is co-corresponding author.
SOMA Browser · Study resource · archived
Dr. Meydan wrote the browser’s code and visualizations; the site acknowledges this award.

Sources

Source	What it documents	Archived copy
Task Book project record, 80NSSC22K0254 NASA Task Book	Project, principal investigator and co-investigators, dates, scientific plan, and a bibliography that includes papers coauthored by Dr. Meydan.	Wayback Machine

NASA Human Research Program · 2016–2018

The noncoding genome and epigenome in astronauts

Funder: NASA Human Research Program
Program: An Integrated Framework for Characterization of the Noncoding Genome and Epigenome in Astronauts
Award number: NNX17AB26G
Award period: October 26, 2016 – October 25, 2018 (NASA Task Book).
Principal investigators: Christopher E. Mason (principal investigator); co-investigator Michael Snyder (Stanford University)
Dr. Meydan’s role: Key personnel

This NASA Human Research Program award supported analysis of noncoding genomic and epigenomic changes during human spaceflight. Dr. Meydan contributed computational genomics expertise as key personnel, connecting epigenome analysis with longitudinal research on astronaut molecular responses.

Selected outputs · 3 coauthored publications · 1 resource

Spatial multi-omics of human skin reveals KRAS and inflammatory responses to spaceflight (2024) · Acknowledges NNX17AB26G
Coauthored spatial multi-omics study of skin samples from spaceflight.
Single-cell multi-ome and immune profiles of the Inspiration4 crew (2024) · Acknowledges NNX17AB26G
Coauthored single-cell multi-ome study of the Inspiration4 crew.
The Space Omics and Medical Atlas (SOMA) and international astronaut biobank (2024) · Acknowledges NNX17AB26G
Dr. Meydan is co-corresponding author.
SOMA Browser · Study resource · archived
Dr. Meydan wrote the browser’s code and visualizations; the site lists NNX17AB26G among its support.

Sources

Source	What it documents	Archived copy
Task Book project record, NNX17AB26G NASA Task Book	Project title, principal investigator and co-investigator, grant number, start and end dates (NASA Human Research Program).	Wayback Machine
SOMA Browser — funding acknowledgments Weill Cornell Medicine	Acknowledges NASA NNX17AB26G among the grants supporting the SOMA data resource, whose code and visualizations are by Dr. Meydan.	Wayback Machine

NIH / NINDS · 2011–2017

Epigenome interactions in complex neurogenetic disorders

Funder: NIH / National Institute of Neurological Disorders and Stroke
Program: Epigenome Interactions in Complex Neurogenetic Disorders
Award number: R01NS076465
Award period: September 2011 – May 2017 (NIH RePORTER).
Principal investigators: M. Elizabeth Ross (contact PI) and Christopher E. Mason, Weill Cornell Medicine
Dr. Meydan’s role: Key personnel

This NINDS-funded project studied interactions between genetic and epigenetic variation in complex neurogenetic disorders. Dr. Meydan contributed genomic analysis and computational research expertise as key personnel, reflecting an earlier phase of his work integrating heterogeneous molecular data.

Selected outputs · 2 coauthored publications

Combination targeted therapy in IDH2- and TET2-mutant AML (2017) · Acknowledges R01NS076465
Co-first-authored Cancer Discovery study of combination targeted therapy in IDH2- and TET2-mutant AML.
Haplotype diversity and sequence heterogeneity of human telomeres (2021) · Acknowledges R01NS076465
Coauthored genome-assembly study of human telomeres.

Sources

Source	What it documents	Archived copy
Epigenome Interactions in Complex Neurogenetic Disorders, R01NS076465 NIH RePORTER	Award number, principal investigators and project dates.	Wayback Machine
Grant record and project abstract OpenAlex	Indexed award record and abstract.	Wayback Machine
Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome (Nature Methods, 2015) Nature Methods	A paper coauthored by Dr. Meydan that acknowledges NS076465 (to C.E. Mason).	Wayback Machine

Earlier international research programs

Selected earlier collaborative research outside the current lab’s central disease areas.

Show earlier project outside the current research focus

European Commission FP7 · 2011–2014

JADE: transnational research clusters for independent living of older adults

Funder: European Commission, Seventh Framework Programme (Regions of Knowledge)
Program: JADE — Joining innovative Approaches for the integration and Development of transnational knowledge of clusters policies related to independent of Elderly
Award number: Grant agreement 266422
Award period: February 2011 – January 2014 (CORDIS).
Principal investigators: Coordinated by Sviluppo Europa Marche (Italy), with 41 participating organizations including Sabancı University (Türkiye)
Dr. Meydan’s role: Key personnel

JADE was a European Commission-supported collaboration on research-driven innovation for independent living among older adults. Dr. Meydan served as key personnel in the Sabancı University-associated work during an earlier stage of his research career.

Sources

Source	What it documents	Archived copy
JADE, grant agreement 266422 European Commission CORDIS	Project, programme, dates and participating organizations.	Wayback Machine

Content reviewed 2026-10-31.